HOME >> MEDICINE >> NEWS
Three Harvard Medical School endowed chairs named simultaneously in sleep medicine

Boston, MA - May 11, 2004 - Harvard Medical School (HMS) is taking steps to dramatically advance the field of Sleep Medicine through the simultaneous establishment of three endowed chairs all devoted to this emerging critical field of medicine.

Joseph B. Martin, Dean of HMS, hailed today's announcement as an historic moment for the school and in the evolution of the field of Sleep Medicine. "This generous and timely support will greatly accelerate advances in sleep and circadian rhythm research. At a time when nearly 40 million Americans suffer with sleep disorders, many find numerous barriers to diagnosis and treatment," said Martin, MD, PhD. "These gifts will enable HMS to take a leading role in this interdisciplinary field, ensuring the advancement of scientific research and the development of new treatments for sleep disorders."

The three chairs are named after the founders and Chairmen of three publicly listed companies that have been innovators in sleep therapy: Dr. Frank Baldino, CEO of Cephalon, Inc., Mr. Gerald E. McGinnis, Board Chairman, of Respironics, and Dr. Peter C. Farrell, CEO of ResMed. Each chair was funded by unrestricted gifts from their companies or themselves.

Recognizing the importance of this scientific discipline, Martin established the Division of Sleep Medicine at HMS in 1997. "The goal of the HMS Division of Sleep Medicine has been to establish sleep disorders medicine as a formally recognized medical discipline, and to forge a path of discovery while providing training for the next generation of national leaders in this discipline," said Martin.

President of Brigham and Women's Hospital, Gary Gottlieb, MD, MBA, concurs, "These three chairs will positively impact research and clinical treatments for dangerous and disabling sleep disorders," he said. "The professorships are being created in honor of visionary leaders in the health care industry."

Martin said that the three men whose names will be on
'"/>

Contact: Judith Montminy
public_affairs@hms.harvard.edu
617-432-0442
Harvard Medical School
11-May-2004


Page: 1 2 3 4 5

Related medicine news :

1. Three-year cervical cancer screening recommendations may be applicable for certain women with HIV
2. Three anti-platelet drugs used in combination are safe
3. Three out of the four million newborn babies who die each year could be saved
4. Three-year health study of teenage girls is underway at Trenton Central High School
5. Three months is too soon to judge a CML patients response to Gleevec, researchers find
6. Three Abbott chemists honored as Heroes for development of HIV therapy for children
7. Three Pfizer Inc chemists win Heroes award for epilepsy treatment for children, adults
8. Three Merck chemists win Heroes of Chemistry award for major asthma treatment advance
9. Three-time Emmy Award winning actress Kathy Baker to participate in ADHD experts on call program
10. Three-month antibiotic treatment reduces risk of future heart attack
11. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference

Post Your Comments:
(Date:8/1/2014)... Cannabis use among young people has spiked, with 29.3 ... marijuana at least once and 17 percent admitting to regular ... Say ‘Yes to Life,’ volunteers from the Church of Scientology ... factual information about drugs, to help reverse this alarming trend. ... Drugs, Say ‘Yes’ to Life,” volunteers have distributed 40,000 copies ...
(Date:8/1/2014)... brain plays a central role in regulating appetite and ... in the brain,s control of food intake and body ... process has been unclear. A new study ... that PPARγ activity in a type of neuron known ... response to high-fat diet. Sabrina Diano and colleagues ...
(Date:8/1/2014)... -- The U.S. Food and Drug Administration announced on ... help fight type 2 diabetes. Jardiance (empagliflozin) ... regimens to control blood sugar levels in the overall ... Office of Drug Evaluation II in the FDA,s Center ... statement. The FDA also recommended that Jardiance be ...
(Date:8/1/2014)... 01, 2014 Summer is here, and with ... during the summer, and they can be a pain for ... to help all their customers get rid of ticks and ... 6,000 eggs in the summer, which is why they are ... tall grass and woodland areas and carry a number of ...
(Date:8/1/2014)... benefits of a cancer diagnosis may improve health outcomes ... conducted by a researcher at the University of Houston ... writing intervention is the writing instruction. Otherwise, writing is ... a journal can be therapeutic, but oftentimes we don,t ... or not," said Qian Lu, assistant professor and director ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:Tis the Season for Tick Prevention 2Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3
(Date:7/31/2014)... SARASOTA, Fla. , July 31, 2014 ... announced today that it has initiated the development of ... ; and that it has selected Quotient Clinical, ... United Kingdom (UK) to run its early ... a Clinical Trial Application (CTA) by the end of ...
(Date:7/31/2014)... Mass. , July 31, 2014  Decision Resources ... technology market intelligence product Marketrack to now include ChinaTrack; ... device landscape in an interactive dashboard providing detailed ... procedure volumes at a hospital level. Other ... , Updated data feed: In addition to end-user surveys ...
(Date:7/31/2014)... VALLEJO, Calif. , July 31, 2014 ... announce it has been selected as the recipient of ... Foundation, which will allow the University to increase research ... is about creating state-of-the-art technology for the study of ... that enhance the diverse needs and interests of our ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Touro University California Garners Grant From Long Foundation 2
Cached News: